Business Context and Reporting Period
Kura Oncology, Inc. filed a Form 8-K Current Report on March 10, 2023. The filing addresses media reports regarding potential liquidity concerns at Silicon Valley Bank (SVB).
Key Financial Metrics
The filing does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. It is a disclosure regarding a specific event rather than a periodic financial report.
Material Changes
No material financial changes were reported. The company stated that its exposure to any liquidity concern at SVB is immaterial.
Management Commentary and Risks
- SVB Exposure: Management acknowledged awareness of media reports concerning SVB but characterized the company's exposure as immaterial.
- Regulatory Status: The information is furnished under Regulation FD and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the total amount of cash and cash equivalents held at Silicon Valley Bank in the most recent 10-Q or 10-K filing.
- Confirm the company's overall cash runway and liquidity position as of the latest reporting period.
- Monitor subsequent filings for any updates regarding the resolution of SVB-related concerns.